Compare BridgeBio Pharma Inc (BBIO) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Star Bulk Carriers Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Star Bulk Carriers Corp trades at $27.66 (market cap $3.17B). The key difference: BridgeBio Pharma Inc is far larger — about 5.2× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 6.62% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | SBLK | |
|---|---|---|
Market Cap | $16.61B | $3.17B |
Sector | Health | Industrials |
52-Week High | $90.17 | $29.15 |
52-Week Low | $47.29 | $16.79 |
Enterprise Value | $18.16B | $3.65B |
Dividend Yield | — | 6.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Star Bulk Carriers (SBLK) trades at $28.90, up 1.08% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $1.21 per share, and declared a $0.90 dividend. Fundamentals show robust profitability with a net income margin of 23.87% and a P/E ratio of 11.15, indicating potential value. Recent news highlights the termination of a vessel sale agreement with Diana Shipping, though the impact appears neutral.
The outlook for SBLK is positive, driven by strong earnings growth, healthy cash flow, and a favorable analyst consensus with 58.34% buy ratings. Key opportunities include high dividend yields and operational efficiency, while risks involve dry bulk rate volatility and competitive pressures in the shipping sector. Investors should weigh the company's solid financials against industry cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
